ArticlePloS one2026
Conservative management of cervical intraepithelial neoplasia grade 2 and immunohistochemical staining of p16 and Ki-67: Data from a Brazilian institution.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical intraepithelial neoplasia grade 2 (CIN2) includes both transient HPV infections and precursor lesions of cervical cancer. Conservative management aims to avoid overtreatment, especially in reproductive-aged women.
objectiveTo describe the clinical outcomes and time to lesion regression among conservatively managed, biopsy-confirmed CIN2 cases, and to explore whether baseline characteristics, including p16 and Ki-67, were associated with lesion regression. MATERIALS AND
methodsAn observational cohort study was conducted in patients with CIN2, as determined by cervical biopsy. Participants were followed up with cytology and colposcopy every 6 months, and outcomes were categorized as regression or no regression. At least two pathologists evaluated p16 immunohistochemical staining according to LAST criteria. Ki-67 staining was considered positive when at least 50% of cells in the lesion were stained, as determined by digital quantification. Bivariate analysis and survival curve analyses were conducted, with significant associations defined as p-values <0.05.
resultsFifty patients with a mean age of 30.5 years were included in the study; 76% (38/50) showed regression. The median time to regression was 357 days (SE = 61.4 days; 95% CI: 236.6-477.4 days). The baseline characteristics, including p16 and Ki-67, were not statistically associated with regression, likely due to the small sample size.
conclusionCIN2 regression occurred in 76% of cases, with median times of approximately 12 months for regression and 32 months for progression. No statistically significant associations were detected between baseline characteristics, including biomarkers, and lesion regression in this exploratory study.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.